All In Biotech

Drug Trial Radar · NCT06055959

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

A Multicenter Open-Label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Activity of Zilucoplan in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

8

Planned (sponsor's estimate)

Start

Oct 16, 2024

Primary completion

May 12, 2027

Study completion Jun 22, 2027

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Sep 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • ZilucoplanDrug

    Zilucoplan will be administered subcutaneously to pediatric study participants.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma concentrations of zilucoplan (ZLP) sampled at Week 4 (Day 29)Time frame: Week 4 (Day 29)
  2. Change from Baseline in sheep red blood cell (sRBC) lysis at Week 4 (Day 29)Time frame: Week 4 (Day 29)
  3. Change from Baseline in complement component 5 (C5) levels at Week 4 (Day 29)Time frame: Week 4 (Day 29)

Locations

9 sites in 5 countries. Site status is shown where the registry gives one.

  • Mg0014 50168

    Chicago, Illinois · Withdrawn

  • Mg0014 50574

    Denton, Texas · Withdrawn

  • Mg0014 40144

    Milan, Italy · Recruiting

  • Mg0014 40774

    Katowice, Poland · Recruiting

  • Mg0014 40218

    Warsaw, Poland · Active not recruiting

  • Mg0014 20104

    Seoul, South Korea · Withdrawn

  • Mg0014 20220

    Seoul, South Korea · Recruiting

  • Mg0014 40735

    Glasgow, United Kingdom · Recruiting

  • Mg0014 40736

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.